Vertex Pharmaceuticals Inc

NASDAQ: VRTX
$450.97
+$0.60 (+0.1%)
Closing Price on November 22, 2024

VRTX Articles

These are the top Wall Street analyst upgrades, downgrades and initiations for Wednesday, June 25, 2014. They include Apple, Coach, J.C. Penney, Micron Technology, Whole Foods and Vertex...
Vertex Pharmaceuticals has reported that two Phase 3 studies of its lumacaftor cystic fibrosis drug in combination with its Kalydeco ivacaftor showed positive results. Shares spikes on the news.
In a new report, the analysts at health care boutique Leerink highlight numerous upcoming catalysts for some top stocks in the sector. Catalysts may move the stocks sharply either way, depending on...
Here are the four top biotech names we found that all have hepatitis C drugs in their current pipelines at one stage or another and that could be the next takeover targets.